Prostate Testing for Cancer and Treatment (ProtecT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02044172 |
Recruitment Status :
Active, not recruiting
First Posted : January 23, 2014
Last Update Posted : November 14, 2022
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | January 21, 2014 | |||
First Posted Date ICMJE | January 23, 2014 | |||
Last Update Posted Date | November 14, 2022 | |||
Actual Study Start Date ICMJE | June 1, 2001 | |||
Actual Primary Completion Date | November 14, 2020 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
Disease specific mortality [ Time Frame: Median 15 years follow up ] | |||
Original Primary Outcome Measures ICMJE |
Disease specific mortality [ Time Frame: Median 10 years follow up ] | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
|
|||
Original Secondary Outcome Measures ICMJE |
|
|||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | Prostate Testing for Cancer and Treatment | |||
Official Title ICMJE | The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer | |||
Brief Summary | RATIONALE: Radical prostatectomy is surgery to remove the entire prostate. Radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells. Sometimes the tumor may not need treatment until it progresses. In this case, active surveillance may be sufficient. It is not yet known which treatment regimen is more effective for localized prostate cancer. PURPOSE: This randomized phase III trial is studying active monitoring to see how well it works compared with radical prostatectomy or radiation therapy in treating patients with localized prostate cancer. |
|||
Detailed Description | OBJECTIVES:
OUTLINE: This is a multicenter study. Patients are stratified by age (50-55 vs 56-59 vs 60-65 vs 66-69 years), Gleason score (6, 7, 8-10), and average result of recruitment and first biopsy prostate-specific antigen (PSA) tests (< 6 vs 6-9.9 vs ≥ 10 ng/mL). Patients are randomized or select a treatment to be followed up in a cohort study. |
|||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Not Applicable | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Prostate Cancer | |||
Intervention ICMJE |
|
|||
Study Arms ICMJE |
|
|||
Publications * |
|
|||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Active, not recruiting | |||
Actual Enrollment ICMJE |
82849 | |||
Original Actual Enrollment ICMJE |
100000 | |||
Estimated Study Completion Date ICMJE | March 31, 2027 | |||
Actual Primary Completion Date | November 14, 2020 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Fit for the treatments and estimates life expectancy of 10 years Registration with eligible primary care practice Exclusion Criteria: Unable to give written informed consent. Concomitant or past malignancy. |
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 50 Years to 69 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United Kingdom | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02044172 | |||
Other Study ID Numbers ICMJE | HTA96/20/99 20141297 ( Registry Identifier: ISRCTN ) |
|||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | University of Oxford | |||
Original Responsible Party | Same as current | |||
Current Study Sponsor ICMJE | University of Oxford | |||
Original Study Sponsor ICMJE | Same as current | |||
Collaborators ICMJE | University of Bristol | |||
Investigators ICMJE |
|
|||
PRS Account | University of Oxford | |||
Verification Date | November 2022 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |